AnaptysBio(ANAB) - 2025 Q1 - Quarterly Results

PORTFOLIO UPDATES Rosnilimab (PD-1 depleter and agonist) Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update SAN DIEGO, May 5, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "Our lead program, rosnilimab, delivered impressive three-month Phase 2b efficacy, safety and tolerability ...